– Elvie, a women’s health tech company, raised $97m in Series C funding.
– The round was led by BGF and BlackRock alongside existing investors including Octopus Ventures.
– It brings Elvie to a valuation of $1.2 billion.
– The Series C will be used to drive more growth through geographical expansion (including entering new markets) and diversifying its product portfolio to target other “key stages” in women’s lives.

– Data labeling platform Snorkel AI announced it has raised $85 million in a series C round co-led by Addition and funds and accounts managed by BlackRock, with participation from Greylock, GV, Lightspeed Venture Partners, Nepenthe Capital, and Walden.
– The round, which brings Snorkel’s total raised to $135 million and its valuation to $1 billion, will be used to continue scaling its engineering team, according to CEO Alex Ratner.

– Exo, a handheld ultrasound device and point-of-care workflow platform, raised $220m funding.
– The round was led by RA Capital Management and joined by BlackRock, Sands Capital, Avidity Partners, Pura Vida Investments and prior investors.
– The company plans to use the funding to commercialize its device and to build out its informatics platform.

– PsiQuantum has raised $450m in Series D funding to build the world’s first commercially viable quantum computer.
– The funding round was led by funds and accounts managed by BlackRock, along with participation from insiders including Baillie Gifford and M12 – Microsoft’s venture fund – and new investors including Blackbird Ventures and Temasek.
– PsiQuantum has now raised a total of $665m in funding to date.
– PsiQuantum was founded in 2016 by the world’s foremost quantum computing experts, who understood that a useful quantum computer required fault-tolerance and error correction, and therefore at least 1 million physical qubits.

– Elvie, the revolutionary global health and lifestyle brand developing iconic products for women, announces a $80M (£58m) Series C funding.
– The funding round was led by BGF, with further investment from funds and accounts managed by BlackRock and a consortium including Hiro Capital and Westerly Winds, plus existing investors Octopus Ventures and IPGL.
– Elvie brings together a team of world-class engineers, designers and business minds to develop extraordinary products that improve women’s lives – revolutionizing categories which had been overlooked for many years, including breast pumps and pelvic floor health.

– Carbon Health, a leading omnichannel healthcare provider, announced that it has raised $350m.
– The investment enables Carbon Health to further accelerate its expansion to become the largest primary care provider in the U.S. and fulfill its mission to make high-quality healthcare accessible to everyone.
– The round was led by Blackstone’s Horizon platform with participation from Atreides, Homebrew, Hudson Bay Capital, Intersect Capital, Fifth Wall, Lux Capital, Silver Lake Waterman, and funds and accounts managed by BlackRock.

– Pine Labs from Singapore raised USD600m in funding.
– The round was led by Fidelity Management & Research Company, funds managed by BlackRock, Ishana, Tree Line, and fund advised by Neuberger Berman Investment Advisers LLC.
– The company intends to use the funds to expand operations and its business reach.

– KeepTruckin has raised $190 million in new funding from G2 Venture Partners, Index Ventures, Greenoaks, IVP, Scale Venture Partners, funds managed by BlackRock, and several other leading investors.
– The round values KeepTruckin at over $2 billion.
– The new capital will support KeepTruckin’s strategic priorities by allowing it to continue building innovative AI-powered products, recruiting top-tier talent, and scaling rapidly to meet the needs of businesses that power the physical economy.
– KeepTruckin’s 400,000-strong network of connected vehicles is one of the largest in North America.

– 10x Future Technologies from London develops a cloud native SaaS bank operating system which enables banks to deliver products, services and customer experiences to retail and SME customers.
– The company raised $100m in Series C funding.
– The round was led by BlackRock and Canada Pension Plan Investment Board (CPP Investments) with participation from existing investors JPMorgan Chase, Nationwide, Ping An and Westpac.
– The new investment will be used for the company’s expansion plans into new markets, including North America, as well as further development of its cloud native 10x SuperCore™ platform.

– Bright Peak Therapeutics announced a $107m Series B financing round.
– RA Capital led the round with participation from founding investor Versant Ventures and new investors Fidelity Management & Research Company, Invus, Qatar Investment Authority, funds and accounts managed by BlackRock, Alexandria Venture Investments and an undisclosed leading healthcare investment fund.
– Bright Peak uses a novel technology to chemically synthesize therapeutic cytokines by ligating together customized peptide segments.
– Bright Peak’s platform also allows for the conjugation of its enhanced cytokines as payloads to certain antibodies, creating novel and proprietary “Bright Peak Immunocytokines.”
– Bright Peak Immunocytokines will allow tissue- and cell-specific targeting of the cytokine payload with the added potential for synergistic efficacy through potency-enhancing avidity effects.

– FlixMobility is a Munich, Germany-based provider of a transportation app.
– Series G $650m round was led by Canyon Partners with participation from existing investors General Atlantic, Permira, TCV, HV Capital, Blackrock and Baillie Gifford.
– The company intends to use the funds to expand its network in the US, the UK and Portugal its position in Turkey, France and Eastern Europe, and grow into new markets.

– NiKang Therapeutics Inc. announced the completion of an oversubscribed $200m series C financing led by Cormorant Asset Management, HBM Healthcare Investments and Octagon Capital Advisors with participations from a premier syndicate of funds including new investors EcoR1 Capital, Perceptive Advisors, Wellington Management, Ally Bridge Group, Pavilion Capital, funds and accounts managed by BlackRock, RA Capital Management, Surveyor Capital (a Citadel company), Samsara BioCapital, PFM Health Sciences, Invus, Janus Henderson Investors and Logos Capital.
– All existing investors including CBC Group, RTW Investments, LP, Lilly Asia Ventures, Matrix Partners China, and Casdin Capital participated in the financing.

– Numab Therapeutics AG, a clinical stage biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer and inflammation, announced the closing of a CHF 100 million (approximately USD 110 million) Series C financing.
– The financing was co-led by new investors Novo Holdings and HBM Partners, with participation from additional new investors Forbion via its Forbion Growth Opportunities Fund, Cormorant Asset Management, BVF Partners L.P., RTW Investments L.P., funds and accounts under the management of BlackRock, Octagon Capital Advisors, and existing investors.

– Exscientia is an Oxford, England, UK-based clinical stage pharmatech company using AI to design patient-based drugs.
– SoftBank Vision Fund 2 led the Series D funding round and was joined by previous round lead investors – Novo Holdings and funds managed by Blackrock.
– Other investors included Mubadala Investment Company, Farallon Capital, Casdin Capital, GT Healthcare Capital, Marshall Wace, Pivotal bioVenture Partners, Laurion Capital, Hongkou and Bristol-Myers Squibb.
– In addition to the Series D funding round, SoftBank is providing an additional $300m equity commitment that can be drawn at the company’s discretion.

– Deep Instinct has successfully raised $100m in Series D funding.
– The company’s platform can predict, prevent, and analyze cyberattacks at any touchpoint of the organization from the endpoint through to the network.
– This round was led by funds and accounts managed from BlackRock, with participation from Untitled Investments, The Tudor Group, an investment by Anne Wojcicki, and existing investors, including Millennium, Unbound, and Coatue Management, among others.
– This new capital doubles the investment to date, bringing the total funding to $200m.
– This round will accelerate Deep Instinct’s aggressive growth plans for 2021 and beyond.
– Deep Instinct currently protects customers across North America, Europe, and APAC, with enterprise customers tripling in the last year.

– Trax secured $640m in a Series E financing round.
– The round was led by Softbank Vision Fund 2 and technology-focused funds managed by existing investor BlackRock, Inc.
– New investors include OMERS, one of Canada’s largest defined benefit pension plans, and Sony Innovation Fund by IGV.
– Trax’s cloud platform is accelerating the digital transformation of consumer packaged goods (CPG) companies and grocery retailers by providing granular visibility of rapidly changing store conditions.
– Trax solutions enable users to make timely, data-driven decisions and implement immediate corrective actions.
– As a result, brands and retailers are accelerating growth, reducing costs, and driving awareness and purchase intent.
– Trax empowers its customers to provide the best shopping experiences imaginable.

– SambaNova Systems from Palo Alto develops a software, hardware and services to run AI applications.
– The company raised $676m in Series D funding.
– The round was led by SoftBank Vision Fund 2 with participation from new investors Temasek and GIC, plus existing backers including funds and accounts managed by BlackRock, Intel Capital, GV (formerly Google Ventures), Walden International and WRVI.
– The company intends to use the funds to continue to expand its business reach and development efforts.

– Insitro, a machine learning-driven drug discovery and development company, has raised $400m in a Series C financing.
– The financing was led by Canada Pension Plan Investment Board (CPP Investments), with significant participation from current investors Andreessen Horowitz, funds and accounts advised by T. Rowe Price Associates, Inc., Casdin Capital, and funds and accounts managed by BlackRock as well as ARCH Venture Partners, Foresite Capital, GV, Third Rock Ventures, Two Sigma Ventures, HOF Capital and Alexandria Venture Investments.

– Monte Rosa Therapeutics announced the closing of a $95m Series C financing.
– The proceeds will be used to advance its lead development candidate into the clinic, accelerate pipeline growth and bolster its platform capabilities to rationally design and develop small molecule degraders (also known as molecular glues) that hijack the body’s innate ability to degrade proteins.
– Through this approach, Monte Rosa aims to eradicate undruggable proteins that cause or drive the progression of genomically-defined diseases intractable to standard care, including cancer.
– The financing was led by Avoro Capital Advisors with participation from additional new investors Fidelity Management & Research Company LLC, funds and accounts managed by BlackRock, funds and accounts advised by T. Rowe Price Associates, Inc., and RTW Investments, LP.

– Snyk from Boston is a cloud native application security company.
– The company closed a Series E financing, totaling $300m.
– The round was led by Accel and Tiger Global, with participation from existing investors Addition, Boldstart Ventures, Canaan Partners, Coatue, GV (formally Google Ventures), Salesforce Ventures, Stripes and funds managed by BlackRock; new investors include Alkeon, Atlassian Ventures, Franklin Templeton, Geodesic Capital, Sands Capital Ventures and Temasek.
– The company intends to use the funds to expand its business reach.

– Amunix Pharmaceuticals from South San Francisco develops masked, protease-activated immune-oncology therapeutics to bring the promise of these potent therapies to patients with solid tumor cancers.
– Series B $117m round was led by Viking Global Investors with participation from a premier syndicate of funds, including new investors Bain Capital Life Sciences, BlackRock, Franklin Templeton, Janus Henderson Investors, ArrowMark Partners, Avidity Partners, certain funds managed by Clough Capital Partners, and CaaS Capital Management and existing investors Redmile Group, Venrock, Casdin Capital, Omega Funds, Frazier Healthcare Partners, Longitude Capital, and Polaris Partners.

– OnKure, Inc. raised $55m in a Series B financing.
– Proceeds will be used to advance the Company’s next generation histone deacetylase (HDAC) inhibitors further into clinical development and fund a growing pipeline of earlier stage molecules.
– The financing was led by Acorn Bioventures with participation from additional new investors Cormorant Asset Management, Surveyor Capital (a Citadel company), Samsara BioCapital, Perceptive Advisors and funds and accounts managed by BlackRock.
– In connection with the financing, Isaac Manke, Ph.D., Partner at Acorn Bioventures, and Andrew Phillips, Ph.D., Managing Director at Cormorant Asset Management, will join the OnKure board of directors.

– Amunix Pharmaceuticals, a biopharmaceutical company focused on developing masked, protease-activated immune-oncology therapeutics to bring the promise of these potent therapies to patients with solid tumor cancers, has raised $117m Series B financing.
– The funding round was led by Viking Global Investors with participation from a premier syndicate of funds, including new investors Bain Capital Life Sciences, BlackRock, Franklin Templeton, Janus Henderson Investors, ArrowMark Partners, Avidity Partners, certain funds managed by Clough Capital Partners, and CaaS Capital Management.

– Exscientia is a clinical stage pharmatech company pioneering the use of artificial intelligence (AI) to design new drugs.
– Company raised 100m in Series C funding.
– The round was led by BlackRock with participation from Novo Holdings, Evotec, Bristol Myers Squibb, and GT Healthcare Capital.
– The company intends to use the funds for platform development towards autonomous drug design, extension of its proprietary pipeline into clinical trials and expansion of existing capabilities in biological analytics that support target selection and portfolio development.

– Volocopter is a Bruchsal, Germany-based urban air mobility (UAM) company.
– Company raised €200m in Series D funding.
– The round was led by new investors funds managed by BlackRock, Atlantia S.p.A., Avala Capital, Continental AG, Jericho Capital, NTT via its venture capital arm, Tokyo Century, a Japanese leasing company, family offices, and existing investors Geely, Daimler, DB Schenker, Intel Capital, btov Partners, Team Europe, and Klocke Holding.

– Vividion Therapeutics, a biotechnology company, announced the completion of a $135M Series C financing.
– The financing was co-led by Logos Capital and Boxer Capital.
– Additional new investors in the raise include SoftBank Investment Advisers, Avoro Capital Advisors, funds and accounts managed by BlackRock, RA Capital Management, funds and accounts advised by T. Rowe Price Associates, Inc., Surveyor Capital (a Citadel company), Woodline Partners LP, Acuta Capital and Driehaus Capital Management.